CymaBay Therapeutics - CBAY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 214.29 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
+0 (0.00%)

This chart shows the closing price for CBAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CymaBay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBAY

Analyst Price Target is $11.00
▲ +214.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 214.29% upside from the last price of $3.50.

This chart shows the closing price for CBAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in CymaBay Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022B. RileyLower TargetBuy$10.00 ➝ $8.00High
5/16/2022OppenheimerLower TargetNA$12.00N/A
5/16/2022HC WainwrightLower TargetNA$12.00 ➝ $10.00Medium
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
11/11/2021Raymond JamesBoost TargetStrong-Buy$12.00 ➝ $14.00High
8/18/2021B. RileyLower TargetBuy$13.00 ➝ $10.00Medium
8/15/2021SVB LeerinkReiterated RatingBuy$10.00High
8/3/2021HC WainwrightLower TargetBuy$13.00 ➝ $12.00Low
6/21/2021JonestradingReiterated RatingBuy$8.00Medium
6/14/2021JonestradingInitiated CoverageBuy$8.00Medium
5/18/2021SVB LeerinkReiterated RatingBuy$10.00Medium
3/31/2021Cantor FitzgeraldLower TargetHold ➝ Overweight$20.00 ➝ $7.00Medium
3/9/2021Piper SandlerReiterated RatingBuy$12.00Low
11/30/2020Smith Barney CitigroupBoost Target$9.00 ➝ $10.00Low
11/6/2020Raymond JamesBoost TargetStrong-Buy$11.00 ➝ $12.00High
11/6/2020SVB LeerinkBoost TargetOutperform$8.00 ➝ $10.00High
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
9/29/2020Lifesci CapitalReiterated RatingOutperformMedium
9/10/2020OppenheimerReiterated RatingBuy$14.00Medium
9/9/2020B. RileyBoost Target$9.00 ➝ $13.00High
8/25/2020CitigroupBoost TargetBuy$7.00 ➝ $9.00Medium
8/12/2020B. RileyReiterated RatingBuy$9.00Low
8/11/2020Raymond JamesBoost TargetStrong-Buy$10.00 ➝ $11.00High
8/4/2020Cantor FitzgeraldBoost TargetOverweight$15.00 ➝ $20.00High
8/4/2020HC WainwrightBoost TargetBuy$9.00 ➝ $13.00High
8/4/2020B. RileyReiterated RatingBuy$9.00High
8/3/2020OppenheimerInitiated CoverageBuy$12.00High
8/3/2020Stifel NicolausBoost TargetHold ➝ Buy$8.00 ➝ $13.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$12.00High
7/23/2020OppenheimerBoost TargetHold ➝ Outperform$6.00 ➝ $10.00High
7/23/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
6/22/2020B. RileyReiterated RatingBuy$6.00High
5/26/2020HC WainwrightUpgradeNeutral ➝ Buy$9.00Medium
5/15/2020CitigroupBoost TargetBuy$1.60 ➝ $7.00Low
5/12/2020B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $6.00Medium
5/12/2020Roth CapitalUpgradeNeutral ➝ Buy$15.00High
5/12/2020Cantor FitzgeraldBoost TargetHold ➝ Overweight$5.00 ➝ $15.00High
5/12/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$2.50 ➝ $6.00High
5/12/2020Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $8.00High
5/12/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$7.00High
5/12/2020Evercore ISIUpgradeIn-Line ➝ Outperform$15.00High
3/20/2020CitigroupLower TargetBuy$2.00 ➝ $1.60Low
3/18/2020B. RileyLower TargetNeutral$2.00 ➝ $1.50High
3/13/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$2.00 ➝ $5.00High
3/12/2020OppenheimerUpgradeMarket Perform ➝ Buy$4.00High
1/30/2020HC WainwrightReiterated RatingHoldHigh
1/2/2020SVB LeerinkReiterated RatingMarket PerformMedium
12/20/2019HC WainwrightReiterated RatingNeutralLow
11/27/2019B. RileyReiterated RatingHold$2.00Low
11/26/2019Roth CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $2.00High
11/26/2019HC WainwrightDowngradeBuy ➝ Neutral$16.00 ➝ $2.00High
11/26/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$20.00 ➝ $2.00High
11/26/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
11/25/2019OppenheimerDowngradeOutperform ➝ HoldN/A
11/25/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
11/25/2019Stifel NicolausDowngradeBuy ➝ Hold$4.00N/A
11/24/2019Evercore ISIReiterated RatingBuy$12.00High
11/6/2019HC WainwrightReiterated RatingBuyMedium
9/18/2019Cantor FitzgeraldSet TargetBuy$20.00Low
8/14/2019Evercore ISIReiterated RatingBuy$15.00Low
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00Low
6/17/2019B. RileySet TargetHold$7.00Low
6/13/2019CitigroupLower TargetBuy$21.00 ➝ $12.00High
6/12/2019HC WainwrightReiterated RatingBuy$24.00 ➝ $12.00Low
6/11/2019B. RileySet TargetHold$11.00High
6/11/2019OppenheimerSet TargetBuy$12.00High
6/11/2019Piper Jaffray CompaniesLower TargetOverweight ➝ Buy$30.00 ➝ $8.00High
5/14/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
4/23/2019Raymond JamesSet TargetBuy$18.00Low
4/14/2019OppenheimerSet TargetBuy$18.00Medium
4/14/2019Cantor FitzgeraldSet TargetBuy$20.00Medium
3/1/2019Piper Jaffray CompaniesSet TargetBuy$30.00High
2/28/2019Cantor FitzgeraldSet TargetBuy$20.00High
2/22/2019SVB LeerinkInitiated CoverageOutperform$22.00High
2/21/2019SVB LeerinkReiterated RatingOutperformMedium
2/20/2019Piper Jaffray CompaniesSet TargetBuy$30.00Low
2/19/2019Roth CapitalReiterated RatingBuyLow
2/15/2019OppenheimerSet TargetBuy$18.00High
2/5/2019B. RileyInitiated CoverageHold$9.00 ➝ $9.00Medium
2/1/2019Cantor FitzgeraldReiterated RatingBuy$20.00High
12/9/2018OppenheimerSet TargetBuy$18.00Medium
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/19/2018HC WainwrightReiterated RatingBuyHigh
11/13/2018OppenheimerSet TargetBuy$18.00Low
11/7/2018OppenheimerSet TargetBuy$18.00Low
11/7/2018Cantor FitzgeraldSet TargetBuy$17.00High
10/5/2018OppenheimerSet TargetBuy$20.00Low
8/10/2018Piper Jaffray CompaniesBoost TargetOverweight$30.00Low
8/9/2018OppenheimerSet TargetBuy$20.00High
8/9/2018Cantor FitzgeraldReiterated RatingBuy$16.00High
6/28/2018Raymond JamesInitiated CoverageOutperform$20.00Medium
6/6/2018HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00Medium
5/9/2018OppenheimerSet TargetBuy$20.00High
4/17/2018OppenheimerSet TargetBuy$20.00Low
4/13/2018HC WainwrightBoost TargetBuy$21.00Low
4/11/2018OppenheimerSet TargetBuy$18.00Medium
4/11/2018SVB LeerinkBoost TargetOutperform$16.00 ➝ $20.00High
3/28/2018HC WainwrightInitiated CoverageBuy$18.00Medium
3/21/2018OppenheimerReiterated RatingBuyMedium
3/16/2018SunTrust BanksReiterated RatingBuy$19.00High
3/16/2018Piper Jaffray CompaniesReiterated RatingBuy$16.00High
3/16/2018Cantor FitzgeraldReiterated RatingBuy$16.00Low
3/12/2018OppenheimerSet TargetBuy$18.00High
2/13/2018Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
1/25/2018Roth CapitalReiterated RatingBuy ➝ Buy$27.00High
1/24/2018HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $18.00High
1/10/2018OppenheimerSet TargetBuy$15.00Medium
11/28/2017SVB LeerinkReiterated RatingBuy$16.00High
11/28/2017HC WainwrightReiterated RatingBuy$12.00Low
11/8/2017Cantor FitzgeraldReiterated RatingBuy$16.00N/A
10/30/2017OppenheimerSet TargetBuy$15.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.
CymaBay Therapeutics logo
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Read More

Today's Range

Now: $3.50
Low: $3.47
High: $3.60

50 Day Range

MA: $3.70
Low: $3.13
High: $4.25

52 Week Range

Now: $3.50
Low: $1.67
High: $4.74


254,691 shs

Average Volume

370,940 shs

Market Capitalization

$296.38 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Raymond James, and
View the latest analyst ratings for CBAY.

What is the current price target for CymaBay Therapeutics?

4 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 214.3%. Raymond James has the highest price target set, predicting CBAY will reach $14.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.00 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.

What is the current consensus analyst rating for CymaBay Therapeutics?

CymaBay Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics.
View the latest ratings for CBAY.

What other companies compete with CymaBay Therapeutics?

How do I contact CymaBay Therapeutics' investor relations team?

CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (510) 293-8800 and its investor relations email address is [email protected] The official website for CymaBay Therapeutics is Learn More about contacing CymaBay Therapeutics investor relations.